Raymond James has recently resumed ADMA Biologics Inc (ADMA) stock to Strong Buy rating, as announced on July 19, 2023, according to Finviz. Earlier, on October 13, 2022, Mizuho had initiated the stock to Buy, setting a price target of $5. Raymond James also raised Strong Buy rating with a price target of $5. Additionally, Cantor Fitzgerald initiated Overweight rating on November 9, 2021, with a target price of $4.50. Jefferies analysts, in their report published on June 4, 2019, also initiated Buy rating and set a price target of $8 for ADMA Biologics Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
ADMA Biologics Inc (ADMA) Stock Trading Recap
On Tuesday, ADMA Biologics Inc (ADMA) stock saw a modest uptick, ending the day at $16.17 which represents a slight increase of $0.27 or 1.70% from the prior close of $15.9. The stock opened at $16.02 and touched a low of $16.02 during the day, reaching a high of $16.57. The volume of shares traded was 2.08 million falling short of the average volume of 2.42 million.
Sponsored
ADMA Stock Performance and Moving Averages
In recent trading, ADMA Biologics Inc (ADMA) stock price has shown some volatility, fluctuating -2.94% over the last five trades and -2.77% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -8.07%, and it has plunged by -24.69% in the previous three months. Currently, ADMA is trading at -1.00%, -7.04%, and 4.02% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, ADMA, a Healthcare sector stock, is trading -31.60% below its 52-week high but remains 222.11% above its 52-week low. The Average True Range (ATR) (14 days) of 0.68 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
ADMA Biologics Inc’s Profitability and Valuation Ratios
ADMA Biologics Inc’s profitability metrics reveal financial health. The company currently boasts an operating margin of 30.01% and a profit margin of 17.80%, with a gross margin of -8.07%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, ADMA Biologics Inc’s market capitalization stands at $3.82 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. The stock’s price-to-earnings (P/E) ratio is 58.52, assessing the company’s valuation relative to its earnings. The forward P/E ratio, which uses projected earnings for the next financial year, is 22.99. Additionally, the Price-to-Sales Ratio is 9.99, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 16.48, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 3.37% of ADMA Biologics Inc (ADMA)’s shares, while financial institutions hold 87.17%.
Notable insider trades include Tade Brad L., CFO and Treasurer at ADMA Biologics Inc (ADMA), who sold 15000 shares on Nov 22 ’24, at $21.15 each, totaling $0.32 million. On Nov 22 ’24, Grossman Adam S, President and CEO, sold 48967 shares for $21.1 each, amounting to $1.03 million. Additionally, on Sep 09 ’24, Guiheen Lawrence P. sold 9000 shares at $18.47 each, generating $0.17 million.
